Menu

Report Detail

Publication Date: May 4, 2022
Purchase Price: $4,750.00
View Report Gallery

Prostate Cancer Diagnostics and Minimally Invasive Treatments Market

Over 1.4 million new cases of prostate cancer were recorded in 2020 worldwide, accounting for approximately 7.3% of all new cancer cases. There were an estimated 375,000 deaths from the disease in 2020, or 3.8% of cancer deaths worldwide. In 2020, combined sales of prostate cancer diagnostics and minimally invasive treatments totaled more than $1.4bn. The main drivers of the prostate cancer diagnostics and minimally invasive treatments market include the increasing incidence of prostate cancer worldwide, an expanding elderly demographic, improved early diagnosis guidelines, increasing patient awareness pertaining to prostate cancer, as well as technological advancements allowing more accurate and precise diagnosis and targeting of more aggressive types of cancer at an earlier stage. Factors that are anticipated to restrain market growth during the forecast period include the lack of population-based screening programs, country-specific reimbursement issues, increased regulatory oversight, and the high cost of some prostate cancer diagnostic and treatment technologies. This comprehensive medical market and technology report provides an overview and in-depth market analysis of selected next-generation prostate cancer diagnostics, biopsy, and minimally invasive treatments. For the purpose of this report, diagnostic technologies include in vitro diagnostics, liquid biopsy, and image-guided biopsy. Prostate cancer treatment options covered by this analysis include minimally invasive treatments such as robotic-assisted laparoscopic prostatectomy (RALP), radiation treatment, and ablation techniques. Drug treatments are not covered in this report. Countries covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of World. The forecast range for this report is 2020–25.

Related Medtech Insight articles:

Back to the top Back to the top